-- Changchun High-Tech Industry (SHE:000661) unit Jinsai Pharmaceutical received China's regulatory approval to conduct clinical trials for vuxin qibai monoclonal antibody injection, according to a Wednesday filing with the Shenzhen bourse.
The drug targets non-infectious uveitis, an eye inflammation.